Phase 3Completed

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

Sponsor
Eli Lilly and Company (Industry)
Enrolment
2,335 enrolled
Conditions
Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea
Interventions
Retatrutide; Placebo
Ages
adults, older adults
Registry
NCT05929066

From the registry

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.

Primary outcomes

  • Percent Change From Baseline in Body Weight
  • Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset
  • Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset
  • Percent Change from Baseline in Body Weight in Participants in Extension Subset
Full record on ClinicalTrials.gov

Papers citing this trial

In the news